This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: C05 (C05.0 hard palate, C05.1 soft palate, C05.2 uvula, C05.9 unspecified) | Special Copayment Reduction: V193 (copayment 5% for care of the relevant condition for 5 years from the date of cancer patient registration) |
| B. Synonyms | Palatal cancer, cancer of the palate, hard palate cancer, soft palate cancer; Hard palate carcinoma, Soft palate carcinoma, Palatine carcinoma, Palatal squamous cell carcinoma |
| C. Adult onset | Likelihood of first onset in adulthood very high — mostly diagnosed in the 40s–70s; HPV-related soft palate cancer also occurs in relatively younger age groups |
| 1. History | Development of separate clinical recognition of hard and soft palate cancer, establishment of radiotherapy and surgery in the 20th century, recognition of the diversity of minor salivary gland origins |
| 2. Causes | Hard palate: smoking, reverse smoking, minor salivary gland carcinogenesis; soft palate: HPV-16, smoking, alcohol; immunosuppression, oral hygiene |
| 3. Genetics | Squamous cell carcinoma: TP53, CDKN2A, FAT1 mutations; adenocarcinoma of minor salivary gland origin: MYB-NFIB (adenoid cystic), MAML2 (mucoepidermoid); soft palate: HPV E6/E7 |
| 4. General epidemiology | Hard palate cancer: relatively rare among oral cancers (5–7%), male predominance, 50s–70s; soft palate cancer: about 10–15% of oropharyngeal cancers |
| 5. Pathophysiology | Hard palate: multistep carcinogenesis of keratinized mucosa; soft palate: HPV E6/E7 oncoproteins, Wnt and EGFR pathways; minor salivary gland origin: distinct molecular mechanisms |
| 6. Symptoms | Hard palate: palatal ulcer, pain, oronasal fistula; soft palate: soft palate dysfunction, hypernasality, dysphagia, trismus |
| 7. Signs | Ulcerative palatal mass, findings of maxillary sinus and nasal cavity invasion, cervical (level II) lymphadenopathy, signs of skull base invasion |
| 8. Screening | Visual oral examination, regular dental checkups, intensive surveillance in reverse-smoking cultures, early suspicion of minor salivary gland tumors |
| 9. Diagnosis | CT (including maxillary sinus and nasal cavity), MRI, PET-CT, biopsy, pathology (SCC vs minor salivary gland origin), p16/HPV testing (soft palate), AJCC 8th edition staging |
| 10. Treatment | Hard palate cancer: surgery (maxillectomy ± reconstruction); soft palate cancer: concurrent chemoradiotherapy or surgery (TORS); IMRT, pembrolizumab, nivolumab |
| 11. Prognosis | Hard palate 5-year survival about 50–60%; soft palate HPV+ over 80%, HPV– 40–50%; minor salivary gland origin varies greatly by histologic type |
| 12. Prevention | Smoking cessation (including reverse smoking) and moderate drinking, HPV vaccine (prevention of soft palate cancer), oral hygiene, regular checkups |
| 13. References | Treatment Outcomes of SCCSP and the Prognostic Significance of HPV/p16 Status (PMC, 2025) ... and 9 other papers |
Malignant neoplasms of the palate are divided by location into hard palate carcinoma (C05.0) and soft palate carcinoma (C05.1), which differ in clinical, epidemiological and therapeutic characteristics. The hard palate is classified as part of the oral cavity and the soft palate as part of the oropharynx.
Historically, records of palatal tumors have existed since antiquity, but modern surgical treatment began in earnest in the 19th century. Maxillectomy was attempted by 19th-century European surgeons for tumors of the hard palate and maxillary sinus, and later developed into a more systematic procedure with advances in anesthesia and asepsis. Because the soft palate is difficult to access surgically and functional damage is severe, radiotherapy was long preferred.
In the mid-20th century, the distinctive pathological features of palatal tumors of minor salivary gland origin (adenoid cystic carcinoma, mucoepidermoid carcinoma, etc.) were established. Unlike squamous cell carcinoma, they have low radiosensitivity and a strong tendency toward perineural invasion, leading to differentiated treatment strategies. Another epidemiologically important finding was the identification of reverse smoking (smoking a chutta/cheroot with the lit end inside the mouth) as a major cause of hard palate cancer in some regions such as India.
In the 21st century, research on the association between HPV and soft palate cancer progressed, and it became apparent that, unlike other oropharyngeal sites (base of tongue, tonsil), the prognostic significance of HPV in soft palate cancer is not clear. The introduction of TORS made minimally invasive surgery of the soft palate possible, and IMRT contributed to reducing radiation side effects on structures around the soft palate.
The causes of palatal cancer differ in part between the hard palate and the soft palate.
Smoking is the main risk factor for hard palate cancer. In particular, reverse smoking—practiced in India, Sri Lanka and elsewhere, in which the lit end is placed inside the mouth—directly exposes the hard palate mucosa to heat and carcinogens, raising the risk of hard palate cancer by tens of times. Because minor salivary glands are densely concentrated in the hard palate, malignancies of minor salivary gland origin (adenoid cystic carcinoma, mucoepidermoid carcinoma, acinic cell carcinoma) are relatively common. Poor oral hygiene and chronic palatal irritation are supplementary risk factors.
HPV-16 infection is an important risk factor for soft palate cancer, and this association becomes more prominent when the soft palate is classified as part of the oropharynx. However, the HPV proportion in soft palate cancer is lower than in other oropharyngeal sites (tonsil, base of tongue). Smoking and alcohol also act as major risk factors. Immunosuppression and poor oral hygiene also increase the risk of soft palate cancer.
Squamous cell carcinomas of the hard and soft palate show genetic alteration patterns similar to oral and oropharyngeal squamous cell carcinomas. TP53 mutations, CDKN2A deletion, and FAT1, NOTCH1 and PIK3CA alterations are commonly observed. HPV-positive squamous cell carcinoma of the soft palate is characterized by loss of TP53 and Rb function due to E6/E7 and by p16 overexpression. However, recent studies have found that HPV/p16 positivity in soft palate cancer does not confer the clear prognostic benefit seen in other oropharyngeal cancers.
Adenoid cystic carcinoma (ACC) arising in the hard palate is characterized by the MYB-NFIB gene fusion, which is being studied as a diagnostic and prognostic marker. Mucoepidermoid carcinoma (MEC) is characterized by MAML2 gene rearrangement (11q21-q23), occurring at high frequency in low-grade MEC. Characteristic molecular alterations have also been identified in acinic cell carcinoma, secretory carcinoma and others.
PD-L1 CPS and TMB are used to determine the indication for immunotherapy in recurrent or metastatic palatal cancer. ACC generally has a low response rate to immunotherapy, but some responses have been reported in cases with NOTCH1 mutations.
Palatal cancer is a relatively rare malignancy arising at the boundary between oral cancer and oropharyngeal cancer.
Hard palate cancer is a rare cancer accounting for about 5–7% of all oral cancers. Men have an incidence about 5 times higher than women, and it occurs mainly in the 50s–70s. Cancers of minor salivary gland origin, along with squamous cell carcinoma, account for an important share in the hard palate. The incidence of hard palate squamous cell carcinoma is particularly high in reverse-smoking cultures such as India and the Philippines.
Soft palate cancer accounts for about 10–15% of oropharyngeal cancers. It is male-predominant and distributed across the 40s–70s. Separate incidence statistics for soft palate cancer in Korea are limited, but it is included in the overall increasing trend of oropharyngeal cancer. Worldwide, soft palate cancer is also increasing somewhat along with the rise of HPV-related oropharyngeal cancer.
The hard palate is covered by keratinized squamous epithelium, beneath which minor salivary glands are abundant. Direct thermal injury and carcinogen exposure from smoking (especially reverse smoking) induce premalignant lesions of the keratinized mucosa. Cancers of minor salivary gland origin form through carcinogenesis of the salivary duct epithelium and have distinctive molecular mechanisms such as the MYB-NFIB gene fusion (ACC) and MAML2 rearrangement (MEC).
The soft palate consists of nonkeratinized squamous epithelium and some minor salivary glands. Expression of the E6/E7 oncoproteins due to HPV infection inactivates p53 and Rb function, inducing cell cycle abnormalities and carcinogenesis. Accumulation of TP53 and CDKN2A mutations due to smoking and alcohol is the carcinogenic mechanism of HPV-negative soft palate cancer. Hyperactivation of the EGFR, PI3K/AKT/mTOR, Wnt and Notch pathways promotes tumor proliferation and invasion.
The early symptom of hard palate cancer is a painless ulcer or mass on the palate. As the tumor progresses, palatal pain, discomfort on chewing and difficulty wearing dentures develop. With maxillary bone invasion, tooth mobility and nonhealing of tooth extraction sites appear. With invasion into the maxillary sinus, an oronasal fistula forms, causing food and liquid to regurgitate into the nose. Nasal obstruction, epistaxis and facial swelling may also appear as symptoms of progression.
The early symptoms of soft palate cancer are relatively nonspecific. A foreign body sensation in the throat, discomfort on swallowing and palatal pain appear early. As soft palate function deteriorates, hypernasality and nasal regurgitation on swallowing occur. With invasion of the posterior pharyngeal wall, severe dysphagia appears, and with pterygoid muscle invasion, trismus develops. A neck mass due to cervical lymph node metastasis may appear early, and otalgia may accompany it.
An ulcerative mass with irregular margins or an exophytic mass is seen on the hard palate. Cancers of minor salivary gland origin often grow by expanding beneath the mucosa, so there may appear to be no visible change. Palatal palpation and radiological examination are essential to evaluate maxillary bone invasion. Cervical level II lymphadenopathy may accompany it.
A mass, ulcer or swelling of the soft palate is confirmed by laryngoscopy or direct inspection of the oropharynx. Abnormal soft palate movement (incomplete velopharyngeal closure during speech) is observed. On CT and MRI, soft palate tumors commonly show muscle invasion and extension to the lateral pharyngeal wall. Cervical level II and III lymphadenopathy is observed. With skull base invasion, neurological symptoms (cranial nerve palsy) accompany it.
The core of screening for palatal cancer is visual oral examination and regular dental checkups. The hard palate is in a location that can be directly inspected, but the soft palate is difficult to inspect completely without laryngoscopy.
With the mouth open, the hard and soft palate are inspected systematically. Ulcers, color changes and masses of the hard palate can be observed directly. For the soft palate, the tongue is pressed down with a tongue depressor and the illuminated area is observed, or a flexible endoscope is used to observe the entire soft palate and uvula. In denture wearers, the dentures must be removed before inspecting the palate.
Reverse smokers (such as those from India), high-risk smokers and drinkers, immunosuppressed patients and patients with premalignant lesions need intensive surveillance at 3–6-month intervals. When a tumor of minor salivary gland origin is suspected (an expansile submucosal mass), immediate MRI and biopsy are recommended.
CT (including jaw, maxillary sinus and skull base): evaluates maxillary bone, maxillary sinus and nasal cavity invasion in hard palate cancer. MRI (T1, T2, contrast-enhanced): essential for evaluating the extent of soft tissue invasion, perineural invasion (maxillary nerve V2 pathway) and skull base invasion. Perineural invasion is particularly common in cancers of minor salivary gland origin. PET-CT: used to evaluate distant metastasis and cervical lymph node metastasis.
In hard palate cancer, squamous cell carcinoma and cancers of minor salivary gland origin (adenoid cystic carcinoma, mucoepidermoid carcinoma, acinic cell carcinoma, etc.) are important, and the treatment strategy differs greatly according to pathology. Soft palate cancer is mainly squamous cell carcinoma, and p16 immunohistochemistry and HPV testing are performed together. In the AJCC 8th edition, the soft palate is classified with oropharyngeal cancer, and separate staging for HPV-positive/negative disease is the rule, but the prognostic significance of HPV status in soft palate cancer is weaker than in other oropharyngeal sites.
Hard palate cancer is staged with oral cavity cancer staging (AJCC 8th edition oral T/N/M), and soft palate cancer with oropharyngeal cancer staging (separate for HPV-positive/negative). For the hard palate, T4a is invasion of the maxillary sinus, nose or skin, and T4b is invasion of the pterygoid muscles, skull base or internal carotid artery.
For hard palate squamous cell carcinoma, surgery (maxillectomy) is the first-line treatment. Depending on lesion size and extent of invasion, partial maxillectomy (infrastructure maxillectomy) or total maxillectomy is performed. The oronasal defect after resection is restored with an obturator prosthesis or free flap reconstruction. Adenoid cystic carcinoma requires high-dose adjuvant radiotherapy (66 Gy or more) along with surgery, and proton therapy is also considered.
For locally advanced soft palate cancer, concurrent chemoradiotherapy (CRT) is the first-line standard treatment. With IMRT, 66–70 Gy is prescribed to the primary site and neck, with concurrent cisplatin (100 mg/m²) or cetuximab. In early soft palate cancer (T1-T2), surgery via TORS is possible, and surgery alone also shows good results.
Pembrolizumab monotherapy or combination based on KEYNOTE-048, nivolumab based on CheckMate 141, and the cetuximab+EXTREME combination regimen are used.
The overall 5-year survival rate of hard palate squamous cell carcinoma is about 50–60%, and better with early detection. The prognosis of cancers of minor salivary gland origin varies greatly by histologic type. Low-grade mucoepidermoid carcinoma has a favorable 5-year survival rate of over 90%, whereas high-grade adenoid cystic carcinoma frequently develops distant metastasis (lung), lowering long-term survival.
The prognosis of soft palate squamous cell carcinoma depends more on stage and treatment method than on HPV status. Recent studies have confirmed that HPV/p16 positivity does not confer a clear prognostic benefit as it does in other oropharyngeal sites. In early (T1-T2) soft palate cancer, surgery has been reported to show better progression-free and overall survival than CRT. Overall 5-year survival is around 60–80% for HPV-positive and 40–50% for HPV-negative disease.
Impaired soft palate function (incomplete velopharyngeal closure, hypernasality, nasal regurgitation on swallowing) seriously affects quality of life. Speech therapy and swallowing rehabilitation should be included in the treatment plan.
Smoking cessation is the key preventive measure for both hard and soft palate cancer. Stopping the practice of reverse smoking is particularly important for preventing hard palate cancer. Together with moderate drinking, 9-valent HPV vaccination contributes to preventing HPV-related soft palate cancer (oropharyngeal cancer). Maintaining oral hygiene and regular dental checkups are also needed.
Premalignant lesions of the hard and soft palate are detected early through regular visual oral examination and endoscopy. Because tumors of minor salivary gland origin present as expansile submucosal masses, such lesions should be detected early and immediate MRI and biopsy performed. In denture wearers, the dentures are removed and the palatal mucosa is inspected regularly.
Chemoprevention studies with retinoids, COX-2 inhibitors and others are under way but have not been established as clinical standards.
Kano S, Tada H, Otsuki N, et al. Treatment Outcomes of Squamous Cell Carcinoma of the Soft Palate and the Prognostic Significance of HPV/p16 Status. Cancers. 2025;17(7):1112. DOI: 10.3390/cancers17071112
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 1.2026. NCCN. 2025. Available at: https://www.nccn.org
Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048). The Lancet. 2019;394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7
Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck (CheckMate 141). New England Journal of Medicine. 2016;375(19):1856-1867. DOI: 10.1056/NEJMoa1602252
Amin MB, Edge S, Greene F, et al. (eds). AJCC Cancer Staging Manual, 8th Edition. Springer. 2017. ISBN: 978-3-319-40617-6.
Palate Squamous Cell Carcinomas: A Ten-Year Single Institute Experience. Ear, Nose & Throat Journal. 2021;100(4):NP194-NP199. DOI: 10.1177/0145561320927143
Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. The Lancet Oncology. 2010;11(8):781-789. DOI: 10.1016/S1470-2045(10)70017-6
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263. DOI: 10.3322/caac.21834
Long-Term Survival and Recurrence in Oropharyngeal Squamous Cell Carcinoma in Relation to Subsites, HPV, and p16-Status. Cancers. 2021;13(12):2918. DOI: 10.3390/cancers13122918
Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer (TAX 324). New England Journal of Medicine. 2007;357(17):1705-1715. DOI: 10.1056/NEJMoa070956